welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts
source: Molecular Therapy
year: 2018
authors: Iyer PS, Mavoungou LO, Ronzoni F, Zemla J, Schmid-Siegert E, Antonini S, Neff LA, Dorchies OM, Jaconi M, Lekka M, Messina G, Mermod N
summary/abstract:Duchenne muscular dystrophy (DMD) is a lethal muscle-wasting disease currently without cure. We investigated the use of the PiggyBac transposon for full-length dystrophin expression in murine mesoangioblast (MABs) progenitor cells. DMD murine MABs were transfected with transposable expression vectors for full-length dystrophin and transplanted intramuscularly or intra-arterially into mdx/SCID mice. Intra-arterial delivery indicated that the MABs could migrate to regenerating muscles to mediate dystrophin expression. Intramuscular transplantation yielded dystrophin expression in 11%-44% of myofibers in murine muscles, which remained stable for the assessed period of 5 months. The satellite cells isolated from transplanted muscles comprised a fraction of MAB-derived cells, indicating that the transfected MABs may colonize the satellite stem cell niche. Transposon integration site mapping by whole-genome sequencing indicated that 70% of the integrations were intergenic, while none was observed in an exon.
Muscle resistance assessment by atomic force microscopy indicated that 80% of fibers showed elasticity properties restored to those of wild-type muscles. As measured in vivo, transplanted muscles became more resistant to fatigue. This study thus provides a proof-of-principle that PiggyBac transposon vectors may mediate full-length dystrophin expression as well as functional amelioration of the dystrophic muscles within a potential autologous cell-based therapeutic approach of DMD.
organization: University of Lausanne, Switzerland; University of Geneva, Switzerland; Institute of Nuclear Physics, Polish Academy of Sciences, Poland; Swiss Institute of Bioinformatics, Switzerland; University of Milan, ItalyDOI: 10.1016/j.ymthe.2018.01.021
read more
rareRelated
-
George Dickson, PhDGeorge Dickson is Professor of Molecular...
-
Nearly Half of Duchenne Muscular Dystrophy Patients Are Candidates for Gene TherapiesMore than 40 percent of boys with Duchen...
-
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Progra...Sarepta Therapeutics, Inc., a commercial...
-
Critical scientific aspects that make gene therapy viablehttps://player.vimeo.com/video/275297686...
-
Realizing the promise of gene therapy through collaboration and partnering: Pfizer’s viewGene therapy is a promising approach to ...
-
Clinical trial of gene therapy for Duchenne muscular dystrophy underway at University of Florida HealthScreening has resumed in a clinical tria...
-
NCATS, FDA Co-Host Workshop on Gene Therapy for Rare Diseases“We are now at the point of translatin...